一种用于肝细胞癌的新预后分期系统的验证:JIS评分与CLIP评分的比较
Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.
作者信息
Kudo Masatoshi, Chung Hobyung, Haji Seiji, Osaki Yukio, Oka Hiroko, Seki Toshihito, Kasugai Hiroshi, Sasaki Yo, Matsunaga Takashi
机构信息
Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan.
出版信息
Hepatology. 2004 Dec;40(6):1396-405. doi: 10.1002/hep.20486.
The Japan Integrated Staging score (JIS score), which combines the Child-Turcotte-Pugh classification and tumor-node-metastasis staging, has been proposed as a better prognostic staging system for hepatocellular carcinoma (HCC) than the Cancer of the Liver Italian Program (CLIP) scoring system. In this study, validation was performed among a larger patient population. A total of 4,525 consecutive patients with HCC who had been diagnosed at five institutions were included. Stratification ability, prognostic predictive power, and reproducibility were analyzed and compared with results from the CLIP scoring system. Only 45% (1,951 of 4,525) of all patients were categorized as early stage HCC according to JIS score (0 or 1), whereas 63% (2,878 of 4,525) of the patients were categorized as having a CLIP score of 0 or 1. Significant differences in survival curves were not observed among CLIP scores 3 to 6. In contrast, survival curves showed significant differences among all the JIS scores. The same JIS scoring subgroups showed a similar prognosis, and good internal reproducibility was observed in each of the institutions. Multivariate analysis of the prognosis in all 4,525 patients proved the JIS score to be the best prognostic factor. Furthermore, the Akaike information criteria proved that the JIS scoring system was statistically a better model for predicting outcome than the CLIP scoring system. In conclusion, the stratification ability and prognostic predictive power of the JIS score were much better than that of the CLIP score and were simple to obtain and remember.
日本综合分期评分(JIS评分)结合了Child-Turcotte-Pugh分级和肿瘤-淋巴结-转移分期,已被提出作为一种比意大利肝癌计划(CLIP)评分系统更好的肝细胞癌(HCC)预后分期系统。在本研究中,在更大的患者群体中进行了验证。纳入了在五家机构诊断的总共4525例连续HCC患者。分析了分层能力、预后预测能力和可重复性,并与CLIP评分系统的结果进行了比较。根据JIS评分(0或1),所有患者中只有45%(4525例中的1951例)被归类为早期HCC,而63%(4525例中的2878例)的患者CLIP评分为0或1。CLIP评分3至6之间未观察到生存曲线的显著差异。相比之下,所有JIS评分之间的生存曲线显示出显著差异。相同的JIS评分亚组显示出相似的预后,并且在每个机构中都观察到了良好的内部可重复性。对所有4525例患者的预后进行多变量分析证明JIS评分是最佳预后因素。此外,赤池信息准则证明JIS评分系统在统计学上是比CLIP评分系统更好地预测结果的模型。总之,JIS评分的分层能力和预后预测能力比CLIP评分要好得多,并且易于获得和记忆。